Patents Examined by Deepak Rao
  • GLP-1 receptor modulators
    Patent number: 9474755
    Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: October 25, 2016
    Assignee: Celgene International II SARL
    Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Adam R. Yeager, Enugurthi Brahmachary, Thomas Fowler, Andrew Novak, Premji Meghani, Michael Knaggs
  • Phenyloxadiazole derivatives as PGDS inhibitors
    Patent number: 9469627
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: October 18, 2016
    Assignee: Sanofi
    Inventors: Christopher L. Vandeusen, Franz J. Weiberth, Harpal S. Gill, George Lee, Andrea Hillegass
  • Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
    Patent number: 9464073
    Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: October 11, 2016
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: Ralph Mazitschek, John H. van Duzer
  • Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
    Patent number: 9458112
    Abstract: The present invention relates to compounds of formula I: in which Y, Y1, Y4, Y5, Y6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 4, 2016
    Assignee: NOVARTIS AG
    Inventors: Pascal Furet, Robert Martin Grotzfeld, Wolfgang Jahnke, Darryl Jones, Paul William Manley, Andreas Marzinzik, Saliha Moussaoui, Xavier Francois Andre Pelle, Bahaa Salem, Joseph Schoepfer
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 9458108
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: October 4, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Stepan Vyskocil, Gabriel S. Weatherhead
  • TSPO ligands for cancer imaging and treatment
    Patent number: 9458161
    Abstract: Embodiments of the present invention relates to compounds of the following formula: as well as compositions, methods of imaging and methods of treating subjects comprising the use of the compound, wherein the variables are defined herein.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: October 4, 2016
    Assignee: Vanderblit University
    Inventors: H. Charles Manning, Jason R. Buck, Dewei Tang
  • N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use
    Patent number: 9452120
    Abstract: N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides of formula (1) are described that are potent modulators (e.g., inhibitors) of an androgen receptor, and which are useful, for example, in the treatment of a dermatological disease or disorder; a disease or disorder of the sebaceous gland(s); acne; hyperseborrhoea; oily skin, seborrhoeic dermatitis; hyperpilosity or hirsutism; atopic dermatitis; or androgenic alopecia; especially acne. Also described, are compositions (e.g., pharmaceutical compositions, cosmetic compositions) comprising the compounds; methods of preparing the compositions; methods of modulating (e.g., inhibiting) and androgen receptors using the compounds and/or compositions; and medical and/or cosmetic use of the compounds and compositions.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: September 27, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Cédric Poinsard
  • Protein kinase C inhibitors and methods of their use
    Patent number: 9452998
    Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: September 27, 2016
    Assignee: NOVARTIS AG
    Inventors: Michael Scott Visser, Michael Joseph Luzzio, Julien Papillon
  • Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders
    Patent number: 9447087
    Abstract: Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I).
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 20, 2016
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Matthew B. Boxer, Martin J. Walsh, Li Liu, Cordelle D. Tanega, Min Shen, Kent Lai, Manshu Tang, Douglas S. Auld
  • 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
    Patent number: 9447086
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4 and A are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: September 20, 2016
    Assignee: Hoffmann-LA Roche INC.
    Inventors: Lei Guo, Taishan Hu, Yimin Hu, Buelent Kocer, Xianfeng Lin, Haixia Liu, Alexander V Mayweg, Zongxing Qiu, Hong Shen, Guozhi Tang, Lisha Wang, Guolong Wu, Shixiang Yan, Weixing Zhang, Mingwei Zhou, Wei Zhu
  • Diaminopyrimidines and uses thereof
    Patent number: 9447051
    Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: September 20, 2016
    Assignee: AbbVie Inc.
    Inventors: Tatyana Dekhtyar, Arthur Gomtsyan, M-Akhteruzzaman Molla, Anil Vasudevan, Iok Chan Ng, Mikhail Chafeev
  • Protein kinase inhibitors
    Patent number: 9447102
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: September 20, 2016
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose
  • Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10)
    Patent number: 9447095
    Abstract: The present invention relates to novel pyrimidine derivatives of formula (I) as inhibitors of the enzyme phosphodiesterase 10 (PDE-10), pharmaceutical compositions comprising an effective amount of these compounds and the use of the compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by inhibition of the enzyme Phosphodiesterase 10 such as neurological, psychiatric, respiratory or metabolic diseases.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: September 20, 2016
    Assignee: PALOBIOFARMA S.L.
    Inventors: Juan Camacho Gómez, Julio Castro Palomino Laria
  • Process for the preparation of nilotinib
    Patent number: 9440959
    Abstract: The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: September 13, 2016
    Assignee: Natco Pharma Limited
    Inventors: Amala Kompella, Adibhatla Kali Satya Bhujanga Rao, Sreenivas Rachakonda, Venugopala Krishna Gampa, Venkaiah Chowdary Nannapaneni
  • 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
    Patent number: 9434719
    Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: September 6, 2016
    Assignee: NOVARTIS AG
    Inventors: Thomas Raymond Caferro, Zhuoliang Chen, Young Shin Cho, Abran Q. Costales, Julian Roy Levell, Gang Liu, James R. Manning, Martin Sendzik, Cynthia Shafer, Michael David Shultz, James Sutton, Yaping Wang, Qian Zhao
  • Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
    Patent number: 9428464
    Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: August 30, 2016
    Assignee: CHDI Foundation, Inc.
    Inventors: Stephen Martin Courtney, Michael Prime, William Mitchell, Christopher John Brown, Paula C. De Aguiar Pena, Peter Johnson, Celia Dominguez, Leticia M. Toledo-Sherman, Ignacio Muñoz-Sanjuan
  • Secondary alcohol substituted triazoles as PDE10 inhibitors
    Patent number: 9428492
    Abstract: The present invention is directed to secondary alcohol substituted triazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: August 30, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Christopher D. Cox, Vadim Y. Dudkin, Carol A. McVean, Thomas S. Reger, Justin T. Steen
  • Compounds
    Patent number: 9422272
    Abstract: Compounds of formula (I): are described herein. Compounds of the disclosure are modulators of Kv3 channels and may be used in the prophylaxis or treatment of related disorders.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: August 23, 2016
    Assignee: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Giuseppe Alvaro, Agostino Marasco
  • Substituted benzylpyrazoles
    Patent number: 9422268
    Abstract: Compounds of formula (I) and their use as pharmaceutical.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: August 23, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Marion Hitchcock, Anne Mengel, Anja Richter, Hans Briem, Knut Eis, Vera Pütter, Gerhard Siemeister, Stefan Prechtl, Amaury Ernesto Fernández-Montalván, Christian Stegmann, Simon Holton, Mark Jean Gnoth, Cornelia Preuβe
  • Liver X receptor modulators
    Patent number: 9416135
    Abstract: Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 16, 2016
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: Chengguo Dong, Yi Fan, Katerina Leftheris, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Yajun Zheng, Linghang Zhuang